SCHEMBL4287622

SCHEMBL4287622

c1cc(Nc2nccc(Oc3ccc4[nH]ccc4c3)n2)ccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.48
KDR P35968 6/20 0.44
JAK2 O60674 2/20 0.44
SCN9A Q15858 1/20 0.44
EGFR P00533 1/20 0.42
FLT3 P36888 2/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
MERTK Q12866 1/20 0.41
NTRK2 Q16620 1/20 0.41
FGFR2 P21802 1/20 0.39
PLK4 O00444 1/20 0.39
IGF1R P08069 1/20 0.39
SRC P12931 1/20 0.39
MAPK14 Q16539 1/20 0.39
ULK1 O75385 1/20 0.39
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38
CYP17A1 P05093 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281016 0.91 KDR (0.54) SYKKDRJAK2FLT3FGFR1
SCHEMBL4279265 0.87 SYK (0.46) SYKKDRJAK2FLT3FGFR1
SCHEMBL4287649 0.86 SYK (0.47) SYKKDRJAK2SCN9AEGFR
SCHEMBL4287633 0.84 SYK (0.50) SYKKDRJAK2EGFRFLT3
SCHEMBL4283784 0.83 KDR (0.49) SYKKDRFLT3FGFR1FLT1
SCHEMBL4290886 0.83 KDR (0.49) SYKKDREGFRFLT3FGFR1
SCHEMBL4279286 0.83 KDR (0.49) SYKKDRSCN9AFLT3FGFR1
SCHEMBL4288245 0.83 CDK5 (0.49) SYKKDRJAK2EGFRFLT3
SCHEMBL4287689 0.83 KDR (0.50) SYKKDRFLT3FGFR1FLT1
SCHEMBL4284818 0.82 SYK (0.45) SYKKDRJAK2SCN9AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 SYK 86/4885KDR 165/4885JAK2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.